Growth & profitability
- Revenue has declined 5.9% per year over the past 5 years.
Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
CCCC Financials C4 Therapeutics, Inc.
7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $36M | -$105M | 0.0% | -320.5% | -$99M | — | $75M |
| 2024 | $36M | -$105M | 0.0% | -336.1% | -$65M | — | $55M |
| 2023 | $21M | -$132M | 0.0% | -669.8% | -$109M | $0 | $127M |
| 2022 | $31M | -$128M | 0.0% | -416.6% | -$111M | $11M | $30M |
| 2021 | $46M | -$84M | 0.0% | -179.4% | -$88M | $11M | $76M |
| 2020 | — | -$66M | — | — | -$68M | $10M | $182M |
| 2019 | — | -$34M | — | — | $54M | — | $91M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $6M | -$25M | 0.0% | -451.6% | -$30M | — | $61M |
| Dec '25 | $11M | -$20M | 0.0% | -210.1% | -$22M | — | $75M |
| Sep '25 | $11M | -$32M | 0.0% | -306.4% | -$32M | — | $59M |
| Jun '25 | $6M | -$26M | 0.0% | -441.0% | — | — | $78M |
| Mar '25 | $7M | -$26M | 0.0% | -402.9% | -$33M | — | $51M |
| Dec '24 | $5M | -$35M | 0.0% | -728.4% | -$18M | — | $55M |
| Sep '24 | $15M | -$25M | 0.0% | -183.9% | -$24M | — | $60M |
| Jun '24 | $12M | -$18M | 0.0% | -178.6% | -$5M | — | $73M |
| Mar '24 | $3M | -$28M | 0.0% | -1060.2% | -$18M | — | $90M |
| Dec '23 | $3M | -$35M | 0.0% | -1147.7% | -$24M | $0 | $127M |
| Sep '23 | $11M | -$27M | 0.0% | -251.2% | -$31M | $0 | $61M |
| Jun '23 | $3M | -$36M | 0.0% | -1410.2% | -$19M | $10M | $45M |
| Mar '23 | $4M | -$35M | 0.0% | -963.8% | -$34M | $12M | $49M |
| Dec '22 | $3M | -$37M | 0.0% | -1341.7% | -$31M | $11M | $30M |
| Sep '22 | $7M | -$32M | 0.0% | -481.0% | -$31M | $11M | $50M |
| Jun '22 | $14M | -$27M | 0.0% | -197.9% | -$23M | $11M | $57M |
| Mar '22 | $8M | -$32M | 0.0% | -409.8% | -$27M | $11M | $46M |
| Dec '21 | $20M | -$16M | 0.0% | -76.0% | -$26M | $11M | $76M |
| Sep '21 | $9M | -$25M | 0.0% | -285.3% | -$18M | $11M | $163M |
| Jun '21 | $10M | -$23M | 0.0% | -226.1% | -$19M | $10M | $281M |
Valuation over time
How the market has priced CCCC against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 11.2× (Mar '23) to 13.5× (Jun '26).
P/S
Frequently asked questions
Is CCCC growing its revenue and profit?
Over the past 5 years, C4 Therapeutics, Inc.'s revenue has declined 5.9% per year. These are computed facts, not advice.
How much debt does CCCC have?
As of FY2025, C4 Therapeutics, Inc. reported — of total debt against $75M of cash.
What is CCCC's profit margin?
In FY2025, gross margin was —, operating margin -320.5%, and net margin -292.1%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.